European Heart Journal

Most patients survive acute myocardial infarction (MI). Yet this encouraging development has certain drawbacks: heart failure (HF) prevalence is increasing and patients affected tend to have more comorbidities worsening economic strain on healthcare systems and impeding effective medical management.

خرید پکیج و مشاهده آنلاین مقاله

A systematic review and meta-analysis of beta-blockers and reninâ€“angiotensin system inhibitors for preventing left ventricular dysfunction due to anthracyclines or trastuzumab in patients with breast cancer

Christian Lewinter, Torsten Holm Nielsen, Lars Robert Edfors, Cecilia Linde, John Martin Bland, M LeWinter, John G F Cleland, Lars KÃ¸ber, Frieder Braunschweig, Agneta Mansson-Broberg

doi : 10.1093/eurheartj/ehab843

European Heart Journal, Volume 43, Issue 27, 14 July 2022, Pages 2562â€“2569

Trastuzumab and anthracyclines, often used in the treatment of breast cancer, may impair myocardial function, and reduce left ventricular ejection fraction (LVEF), potentially causing heart failure. Randomized controlled trials (RCTs) have evaluated the effects of beta-blockers (BBs), angiotensin receptor blockers (ARBs), and angiotensin-converting enzyme inhibitors (ACEI) on trastuzumab- and anthracycline-associated cardiotoxicity. We report a meta-analysis of these RCTs in patients with breast cancer.

خرید پکیج و مشاهده آنلاین مقاله

Cardioprotection in breast cancer patients: one size fits all?Â

Geeta Gulati

doi : 10.1093/eurheartj/ehab810

European Heart Journal, Volume 43, Issue 27, 14 July 2022, Pages 2570â€“2572

خرید پکیج و مشاهده آنلاین مقاله

Accelerated and personalized therapy for heart failure with reduced ejection fraction

Li Shen, Pardeep Singh Jhund, Kieran Francis Docherty, Muthiah Vaduganathan, Mark Colquhoun Petrie, Akshay Suvas Desai, Lars KÃ¸ber, Morten Schou, Milton Packer, Scott David Solomon, Xingwei Zhang, John Joseph Valentine McMurray

doi : 10.1093/eurheartj/ehac210

European Heart Journal, Volume 43, Issue 27, 14 July 2022, Pages 2573â€“2587

Previously, guidelines recommended initiating therapy in patients with heart failure and reduced ejection fraction (HFrEF) in a sequence that follows the chronological order in which trials were conducted, with cautious up-titration of each treatment. It remains unclear whether this historical approach is optimal and alternative approaches may improve patient outcomes.

خرید پکیج و مشاهده آنلاین مقاله

Heart failure medication: moving from evidence generation to implementationÂ

Jasper Tromp, Adriaan A Voors

doi : 10.1093/eurheartj/ehac272

European Heart Journal, Volume 43, Issue 27, 14 July 2022, Pages 2588â€“2590

خرید پکیج و مشاهده آنلاین مقاله

Survival of patients undergoing cardiac resynchronization therapy with or without defibrillator: the RESET-CRT project

Moritz Hadwiger, Nikolaos Dagres, Janina Haug, Michael Wolf, Ursula Marschall, Jan Tijssen, Alexander Katalinic, Fabian Simon Frielitz, Gerhard Hindricks

doi : 10.1093/eurheartj/ehac053

European Heart Journal, Volume 43, Issue 27, 14 July 2022, Pages 2591â€“2599

Cardiac resynchronization therapy (CRT) is an established treatment for heart failure. There is contradictory evidence whether defibrillator capability improves prognosis in patients receiving CRT. We compared the survival of patients undergoing de novo implantation of a CRT with defibrillator (CRT-D) option and CRT with pacemaker (CRT-P) in a large health claims database.

خرید پکیج و مشاهده آنلاین مقاله

CRT-P or CRT-D in heart failure patients: the RESET-CRT projectâ€”a prelude to the randomized controlled RESET-CRT studyÂ

Cecilia Linde

doi : 10.1093/eurheartj/ehac136

European Heart Journal, Volume 43, Issue 27, 14 July 2022, Pages 2600â€“2602

خرید پکیج و مشاهده آنلاین مقاله

The GUIDE-HF trial of pulmonary artery pressure monitoring in heart failure: impact of the COVID-19 pandemic

Michael R Zile, Akshay S Desai, Maria Rosa Costanzo, Anique Ducharme, Alan Maisel, Mandeep R Mehra, Sara Paul, Samuel F Sears, Frank Smart, Christopher Chien, Ashrith Guha, Jason L Guichard, Shelley Hall, Orvar Jonsson, Nessa Johnson, Poornima Sood, John Henderson, Philip B Adamson, JoAnn Lindenfeld

doi : 10.1093/eurheartj/ehac114

European Heart Journal, Volume 43, Issue 27, 14 July 2022, Pages 2603â€“2618

During the coronavirus disease 2019 (COVID-19) pandemic, important changes in heart failure (HF) event rates have been widely reported, but few data address potential causes for these changes; several possibilities were examined in the GUIDE-HF study.

خرید پکیج و مشاهده آنلاین مقاله

The COVID-19 pandemic and heart failure: lessons from GUIDE-HFÂ

Martin R Cowie, John G F Cleland

doi : 10.1093/eurheartj/ehac226

European Heart Journal, Volume 43, Issue 27, 14 July 2022, Pages 2619â€“2621

خرید پکیج و مشاهده آنلاین مقاله

Characteristics and natural history of early-stage cardiac transthyretin amyloidosis

Steven Law, Melanie Bezard, Aviva Petrie, Liza Chacko, Oliver C Cohen, Sriram Ravichandran, Olabisi Ogunbiyi, Mounira Kharoubi, Sashiananthan Ganeshananthan, Sharmananthan Ganeshananthan, Janet A Gilbertson, Dorota Rowczenio, Ashutosh Wechalekar, Ana Martinez-Naharro, Helen J Lachmann, Carol J Whelan, David F Hutt, Philip N Hawkins, Thibaud Damy, Marianna Fontana, Julian D Gillmore

doi : 10.1093/eurheartj/ehac259

European Heart Journal, Volume 43, Issue 27, 14 July 2022, Pages 2622â€“2632

Transthyretin amyloid cardiomyopathy (ATTR-CM) is increasingly diagnosed at an early stage of the disease natural history, defined as National Amyloidosis Centre (NAC) ATTR Stage I. The natural history of early-stage ATTR-CM remains poorly characterized.

خرید پکیج و مشاهده آنلاین مقاله